Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
Conclusion and Relevance: There were significant improvements in both visual and anatomical outcomes after switching from bevacizumab or ranibizumab to aflibercept, without risk of adverse events. Thus, switching therapy may be a safe and effective treatment for patients with refractory DME.
PMID: 32005079 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Xiao K, Li FZ, Liang SZ, Wang J, Qian C, Wan GM Tags: Ann Pharmacother Source Type: research
More News: Avastin | Databases & Libraries | Diabetes | Drugs & Pharmacology | Endocrinology | Lucentis | Ranibizumab Injection | Science | Statistics | Study